Novel Substituted Aryl Sulfonamides and Sulfuric Diamides As Transglutaminase 2 Inhibitors
This patent describes novel substituted aryl sulfonamides and sulfuric diamides as potent transglutaminase 2 (TG2) inhibitors. It provides details on the novel substituted aryl sulfonamide and sulfuric diamide compounds, pharmaceutical formulations, and the use of such compounds in the treatment of TG2-related diseases, such as fibrosis, neurodegenerative diseases, autoimmune diseases, and cancers.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Jian Rong (ORCID: https://orcid.org/0000-0002-3960-1669)
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
- Union Hospital (CN)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1021/acsmedchemlett.5c00693
- Primary Topic
- Blood properties and coagulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00